Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial (ChiCTR) - Oct 16, 2026 - P2 | N=66 | Not yet recruiting | Sponsor: West China Hospital of Sichuan University; West China Hospital of Sichuan University
New P2 trial • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • PD-L1 • TFE3
|